Methods and Compositions Related To miR-21 and miR-29A, Exosome Inhibition And Cancer Metastasis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 29, 2016
filing date -
Dec 13, 2011
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Toll-like receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
OHIO STATE INNOVATION FOUNDATION | 1524 NORTH HIGH STREET COLUMBUS OH 43201 |
International Classification(s)

- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Croce, Carlo M | Columbus, US | 177 | 3475 |
# of filed Patents : 177 Total Citations : 3475 | |||
Fabbri, Muller | Los Angeles, US | 6 | 47 |
# of filed Patents : 6 Total Citations : 47 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 8 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 5, 2028 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text
- i. providing a composition comprising one or more ribonucleic acids molecules (RNA),ii. hybridizing to said one or more RNAs, one or more two-part nucleic acid hybridization probes, wherein each probe comprises, a. a first nucleic acid molecule with a 3′-tail wherein said tail does not hybridize to an RNA in the composition,b. a second nucleic acid molecule with a 5′-tail wherein said tail does not hybridize to an RNA in the composition,c. wherein said first and said second nucleic acid molecules when and if hybridized to their target RNA lie on one single stranded RNA molecule separated from each other by between 2 and 1000 nucleotides, iii. covalently linking the hybridized 5′-tail of said first nucleic acid molecule to the hybridized 3′-tail of said second nucleic acid, wherein the linking is done by means of reverse transcription and subsequent ligation,iv. amplifying the linked molecules with primers that are specific for said first 3′-tail of said first nucleic acid molecule and said second 5′-tail of said second nucleic acid molecule and,v. sequencing the amplification products by means of next generation sequencing.

Legal Events
- No Legal Status data available.

Matter Detail

Renewals Detail
